4/24
07:12 am
ntra
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test [Yahoo! Finance]
Low
Report
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test [Yahoo! Finance]
4/24
07:00 am
ntra
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test
Medium
Report
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test
4/22
04:05 pm
ntra
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
Low
Report
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
4/10
11:19 am
ntra
Natera, Inc. (NASDAQ: NTRA) had its price target lowered by analysts at Barclays PLC from $200.00 to $160.00. They now have an "overweight" rating on the stock.
Low
Report
Natera, Inc. (NASDAQ: NTRA) had its price target lowered by analysts at Barclays PLC from $200.00 to $160.00. They now have an "overweight" rating on the stock.
4/8
10:31 am
ntra
Natera, Inc. (NTRA): Among Stocks with Buy Ratings that Hedge Funds Love [Yahoo! Finance]
Medium
Report
Natera, Inc. (NTRA): Among Stocks with Buy Ratings that Hedge Funds Love [Yahoo! Finance]
3/25
08:00 am
ntra
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting [Yahoo! Finance]
Low
Report
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting [Yahoo! Finance]
3/25
07:00 am
ntra
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
Low
Report
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
3/19
02:07 am
ntra
Natera, Inc. (NASDAQ: NTRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Natera, Inc. (NASDAQ: NTRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/15
05:31 am
ntra
Natera, Inc. (NASDAQ: NTRA) was upgraded by analysts at Royal Bank of Canada to a "moderate buy" rating.
Low
Report
Natera, Inc. (NASDAQ: NTRA) was upgraded by analysts at Royal Bank of Canada to a "moderate buy" rating.
3/13
08:23 am
ntra
Natera, Inc. (NASDAQ: NTRA) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $251.00 price target on the stock.
Low
Report
Natera, Inc. (NASDAQ: NTRA) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $251.00 price target on the stock.
3/11
02:07 am
ntra
Natera, Inc. (NASDAQ: NTRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Natera, Inc. (NASDAQ: NTRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/10
11:11 am
ntra
Natera, Inc. (NASDAQ: NTRA) had its "buy" rating re-affirmed by analysts at BTIG Research.
Low
Report
Natera, Inc. (NASDAQ: NTRA) had its "buy" rating re-affirmed by analysts at BTIG Research.
3/10
08:45 am
ntra
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer [Yahoo! Finance]
Medium
Report
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer [Yahoo! Finance]
3/10
08:00 am
ntra
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
Low
Report
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
3/5
09:03 am
ntra
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Morgan Stanley from $176.00 to $185.00. They now have an "overweight" rating on the stock.
Medium
Report
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Morgan Stanley from $176.00 to $185.00. They now have an "overweight" rating on the stock.
3/4
11:59 am
ntra
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Piper Sandler from $200.00 to $205.00. They now have an "overweight" rating on the stock.
Medium
Report
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Piper Sandler from $200.00 to $205.00. They now have an "overweight" rating on the stock.
3/4
07:41 am
ntra
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD [Yahoo! Finance]
Low
Report
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD [Yahoo! Finance]
3/4
07:00 am
ntra
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
Low
Report
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
3/3
11:03 pm
ntra
Natera, Inc. (NASDAQ: NTRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Natera, Inc. (NASDAQ: NTRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/28
09:20 am
ntra
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Robert W. Baird from $183.00 to $188.00. They now have an "outperform" rating on the stock.
Low
Report
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Robert W. Baird from $183.00 to $188.00. They now have an "outperform" rating on the stock.
2/27
04:32 pm
ntra
Natera Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Low
Report
Natera Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
2/27
04:05 pm
ntra
Natera Reports Fourth Quarter and Full Year 2024 Financial Results
Low
Report
Natera Reports Fourth Quarter and Full Year 2024 Financial Results
2/26
12:49 pm
ntra
Natera, Inc. (NASDAQ: NTRA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $180.00 price target on the stock.
Low
Report
Natera, Inc. (NASDAQ: NTRA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $180.00 price target on the stock.
2/25
06:26 am
ntra
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer [Yahoo! Finance]
Low
Report
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer [Yahoo! Finance]
2/25
06:00 am
ntra
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer
Low
Report
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer